This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

This study has been completed.
VA Office of Research and Development
Information provided by (Responsible Party):
Ted Bader, MD, Bader, Ted, M.D. Identifier:
First received: June 15, 2007
Last updated: August 20, 2012
Last verified: August 2012
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert.

Condition Intervention Phase
Chronic Hepatitis C Drug: standard of care Drug: fluvastatin Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Adding Fluvastatin to Standard Medical Treatment (SMT) and a Pilot Trial of Rosuvastatin and Other Statins With SMT, for Patients Infected With Chronic Hepatitis C Who Are Naive to Therapy.

Resource links provided by NLM:

Further study details as provided by Ted Bader, MD, Bader, Ted, M.D.:

Primary Outcome Measures:
  • Sustained Viral response [ Time Frame: 72 weeks ]

Secondary Outcome Measures:
  • Viral load at 4, 12 and 24 weeks [ Time Frame: 24 weeks ]

Enrollment: 40
Study Start Date: June 2007
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1 Plus statin
The addition of fluvastatin or rosuvastatin or other statins to the standard of care of peginterferon and ribavirin.
Drug: fluvastatin
Add fluvastatin at 20-40 mg/day to standard of care
Other Name: Lescol
Active Comparator: 2
Administration of the standard of care for hepatitis C of peginterferon and ribavirin.
Drug: standard of care


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Not previously treated.
  • Off alcohol and marijuana for 6 months
  • HCV RNA positive

Exclusion Criteria:

  • HIV positive
  • Advanced liver disease
  • Advanced cardiopulmonary disease
  • Chronic renal failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00487318

United States, Oklahoma
Veterans Administration Medical Center
Oklahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Bader, Ted, M.D.
VA Office of Research and Development
Principal Investigator: Ted F Bader, MD OUHSC and VAMC
  More Information

Responsible Party: Ted Bader, MD, Director of Liver Diseases, VA Medical Center, Bader, Ted, M.D. Identifier: NCT00487318     History of Changes
Other Study ID Numbers: 13358
Study First Received: June 15, 2007
Last Updated: August 20, 2012

Keywords provided by Ted Bader, MD, Bader, Ted, M.D.:
hepatitis C
chronic hepatitis C
not previously treated with pegylated interferon and ribavirin

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis, Chronic
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Rosuvastatin Calcium
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Enzyme Inhibitors
Lipid Regulating Agents processed this record on August 16, 2017